Skip to main content
Erschienen in: Journal of Gastroenterology 11/2020

09.08.2020 | COVID-19 | Original Article—Liver, Pancreas, and Biliary Tract Zur Zeit gratis

Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19

verfasst von: Yoshihito Uchida, Hayato Uemura, Shinpei Yamaba, Daisuke Hamada, Norihito Tarumoto, Shigefumi Maesaki, Satoshi Mochida

Erschienen in: Journal of Gastroenterology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

COVID-19 has emerged as a threat to human health. Liver dysfunction has been reported to occur frequently in patients with COVID-19, although its significance has not yet been elucidated.

Methods

The subjects were 35 patients with COVID-19, and clinical characteristics were retrospectively analyzed. COVID-19 patients requiring ventilator were classified as having severe COVID-19.

Results

All 35 patients were diagnosed as having mild-to-moderate COVID-19 at admission, but the severity aggravated to severe in 8 patients (22.9%) in hospital. Hepatocellular-type liver injury, defined as elevation of the serum AST and/or ALT levels to ≥ 3 times the ULN, was seen in 2 patients (5.7%), and cholestasis-type liver injury, defined as elevation of the serum ALP, γ-GTP and/or total bilirubin levels to ≥ twice the ULN, was seen in 4 patients (11.4%). A total of 9 patients (25.7%) fulfilled the criteria for liver injury. The percentage of patients with liver injury was higher in patients with severe COVID-19 than in the remaining patients (P = 0.001). Both the hepatic CT attenuation values and the liver-to-spleen attenuation (L/S) ratios at admission were lower in the former patients than in the latter patients (P < 0.001). ROC curve revealed the optimal cut-off value of the L/S ratio of 1.03 for discriminating between patients with severe and non-severe diseases. The hepatic CT attenuation values increased at the remission phase of the disease as compared to the values at admission (P = 0.012).

Conclusion

Liver dysfunction associated with reduced hepatic CT attenuation values correlated with the disease severity in patients with COVID-19.
Literatur
1.
Zurück zum Zitat Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.CrossRef Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.CrossRef
2.
Zurück zum Zitat Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.CrossRef Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–207.CrossRef
5.
Zurück zum Zitat Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159:320.e27–34.e27. Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159:320.e27–34.e27.
6.
Zurück zum Zitat Mao R, Qiu Y, He J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–78.CrossRef Mao R, Qiu Y, He J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:667–78.CrossRef
10.
Zurück zum Zitat Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.CrossRef Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.CrossRef
11.
Zurück zum Zitat Sun J, Aghemo A, Forner A, et al. COVID-19 and liver disease. Liver Int. 2020;40:1278–81.CrossRef Sun J, Aghemo A, Forner A, et al. COVID-19 and liver disease. Liver Int. 2020;40:1278–81.CrossRef
12.
Zurück zum Zitat Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(271–280):e8. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(271–280):e8.
13.
Zurück zum Zitat Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–8.CrossRef Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–8.CrossRef
14.
Zurück zum Zitat Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012:307315.CrossRef Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012:307315.CrossRef
15.
Zurück zum Zitat Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;S0168–8278:30294–304. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;S0168–8278:30294–304.
18.
Zurück zum Zitat Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study. Gastroenterology. 2020;S0016–5085:30585. Singh S, Khan A. Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study. Gastroenterology. 2020;S0016–5085:30585.
19.
Zurück zum Zitat Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;S0168–8278:30206–133. Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;S0168–8278:30206–133.
20.
Zurück zum Zitat Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998–1004.CrossRef Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998–1004.CrossRef
22.
Zurück zum Zitat Yasui S, Fujiwara K, Okitsu K, et al. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res. 2012;42:42–50.CrossRef Yasui S, Fujiwara K, Okitsu K, et al. Importance of computed tomography imaging features for the diagnosis of autoimmune acute liver failure. Hepatol Res. 2012;42:42–50.CrossRef
23.
Zurück zum Zitat Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020;14:297–304.CrossRef Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020;14:297–304.CrossRef
24.
Zurück zum Zitat Fan J, Wang H, Ye G, et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;107:154243.CrossRef Fan J, Wang H, Ye G, et al. Letter to the Editor: Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019. Metabolism. 2020;107:154243.CrossRef
25.
Zurück zum Zitat Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593–602.CrossRef Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593–602.CrossRef
Metadaten
Titel
Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19
verfasst von
Yoshihito Uchida
Hayato Uemura
Shinpei Yamaba
Daisuke Hamada
Norihito Tarumoto
Shigefumi Maesaki
Satoshi Mochida
Publikationsdatum
09.08.2020
Verlag
Springer Singapore
Schlagwort
COVID-19
Erschienen in
Journal of Gastroenterology / Ausgabe 11/2020
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01717-4

Weitere Artikel der Ausgabe 11/2020

Journal of Gastroenterology 11/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.